{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:30:50Z","timestamp":1782761450479,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Puma Biotechnology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12282-020-01133-9","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T20:02:27Z","timestamp":1595102547000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-238X","authenticated-orcid":false,"given":"Kate R.","family":"Secombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen A.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shirren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Wignall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy M.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,18]]},"reference":[{"key":"1133_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05102-x","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, et al. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019. https:\/\/doi.org\/10.1007\/s10549-018-05102-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1133_CR2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0186","author":"MA Cherian","year":"2017","unstructured":"Cherian MA, Ma CX. The role of neratinib in HER2-driven breast cancer. Future Oncol. 2017. https:\/\/doi.org\/10.2217\/fon-2017-0186.","journal-title":"Future Oncol"},{"key":"1133_CR3","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.2147\/ott.s122397","volume":"10","author":"HR Kourie","year":"2017","unstructured":"Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M. Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. Onco Targets Ther. 2017;10:3363\u201372. https:\/\/doi.org\/10.2147\/ott.s122397.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"1133_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(15)00551-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1133_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","volume":"375","author":"JW Park","year":"2016","unstructured":"Park JW, Liu MC, Yee D, Yau C, van Veer LJ, Symmans WF, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1513750.","journal-title":"N Engl J Med"},{"issue":"13","key":"1133_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.4161\/cbt.21783","volume":"13","author":"JM Bowen","year":"2012","unstructured":"Bowen JM, Mayo BJ, Plews E, Bateman E, Stringer AM, Boyle FM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther. 2012;13(13):1269\u201375. https:\/\/doi.org\/10.4161\/cbt.21783.","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"1133_CR7","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jn\/126.10.2519","volume":"126","author":"GS Howarth","year":"1996","unstructured":"Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr. 1996;126(10):2519\u201330.","journal-title":"J Nutr"},{"issue":"6","key":"1133_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.mct-15-0990","volume":"15","author":"HR Wardill","year":"2016","unstructured":"Wardill HR, Gibson RJ, Van Sebille YZ, Secombe KR, Coller JK, White IA, et al. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther. 2016;15(6):1376\u201386. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0990.","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"1133_CR9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/bioinformatics\/bts342","volume":"28","author":"J Chen","year":"2012","unstructured":"Chen J, Bittinger K, Charlson ES, Hoffmann C, Lewis J, Wu GD, et al. Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics (Oxford, England). 2012;28(16):2106\u201313. https:\/\/doi.org\/10.1093\/bioinformatics\/bts342.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"1133_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fmicb.2018.00365","volume":"9","author":"CP McNally","year":"2018","unstructured":"McNally CP, Eng A, Noecker C, Gagne-Maynard WC, Borenstein E. BURRITO: an interactive multi-omic tool for visualizing taxa-function relationships in microbiome data. Front Microbiol. 2018;9:365\u2013365. https:\/\/doi.org\/10.3389\/fmicb.2018.00365.","journal-title":"Front Microbiol"},{"issue":"21","key":"1133_CR11","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1093\/bioinformatics\/btu494","volume":"30","author":"DH Parks","year":"2014","unstructured":"Parks DH, Tyson GW, Hugenholtz P. Beiko RG STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics (Oxford, England). 2014;30(21):3123\u20134. https:\/\/doi.org\/10.1093\/bioinformatics\/btu494.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"1133_CR12","doi-asserted-by":"publisher","DOI":"10.4324\/9780203211250","volume-title":"Diseases of the Wistar rat","author":"MJ Tucker","year":"1997","unstructured":"Tucker MJ. Diseases of the Wistar rat. Routledge: Taylor & Francis; 1997."},{"issue":"3","key":"1133_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659\u201361. https:\/\/doi.org\/10.1096\/fj.07-9574LSF.","journal-title":"FASEB J"},{"issue":"12","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/ijc.30699","volume":"140","author":"YZA Van Sebille","year":"2017","unstructured":"Van Sebille YZA, Gibson RJ, Wardill HR, Secombe KR, Ball IA, Keefe DMK, et al. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. Int J Cancer. 2017;140(12):2820\u20139. https:\/\/doi.org\/10.1002\/ijc.30699.","journal-title":"Int J Cancer"},{"issue":"7","key":"1133_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ctrv.2015.05.011","volume":"41","author":"YZ Van Sebille","year":"2015","unstructured":"Van Sebille YZ, Gibson RJ, Wardill HR. Bowen JM ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 2015;41(7):646\u201352. https:\/\/doi.org\/10.1016\/j.ctrv.2015.05.011.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-012-1857-3","volume":"70","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C. Sonnichsen D A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol. 2012;70(1):191\u20139. https:\/\/doi.org\/10.1007\/s00280-012-1857-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1133_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3756-8","author":"KR Secombe","year":"2018","unstructured":"Secombe KR, Ball IA, Shirren J, Wignall AD, Finnie J, Keefe D, et al. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemother Pharmacol. 2018. https:\/\/doi.org\/10.1007\/s00280-018-3756-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1133_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7150\/jca.13684","volume":"7","author":"L Wang","year":"2016","unstructured":"Wang L, Xiao J, Gu W, Chen H. Sex difference of Egfr expression and molecular pathway in the liver: impact on drug design and cancer treatments? J Cancer. 2016;7(6):671\u201380. https:\/\/doi.org\/10.7150\/jca.13684.","journal-title":"J Cancer"},{"issue":"2","key":"1133_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1124\/pr.115.011163","volume":"68","author":"JB Becker","year":"2016","unstructured":"Becker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. 2016;68(2):242\u201363. https:\/\/doi.org\/10.1124\/pr.115.011163.","journal-title":"Pharmacol Rev"},{"key":"1133_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-642-30726-3_2","volume":"214","author":"S Mahmoodzadeh","year":"2012","unstructured":"Mahmoodzadeh S, Fliegner D, Dworatzek E. Sex differences in animal models for cardiovascular diseases and the role of estrogen. Handb Exp Pharmacol. 2012;214:23\u201348. https:\/\/doi.org\/10.1007\/978-3-642-30726-3_2.","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"1133_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143\u201357. https:\/\/doi.org\/10.2165\/00003088-200948030-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1133_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/138945009788488440","volume":"10","author":"N Al-Dasooqi","year":"2009","unstructured":"Al-Dasooqi N, Gibson R, Bowen J. Keefe D HER2 targeted therapies for cancer and the gastrointestinal tract. Curr Drug Targets. 2009;10(6):537\u201342.","journal-title":"Curr Drug Targets"},{"issue":"7541","key":"1133_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature14232","volume":"519","author":"B Chassaing","year":"2015","unstructured":"Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92\u20136. https:\/\/doi.org\/10.1038\/nature14232.","journal-title":"Nature"},{"key":"1133_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-00020-04040-00280","author":"BJ Mayo","year":"2020","unstructured":"Mayo BJ, Secombe KR, Wignall AD, Bateman E, Thorpe D, Pietra C, et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer Chemother Pharmacol. 2020. https:\/\/doi.org\/10.1007\/s00280-00020-04040-00280.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1133_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/apt.12878","volume":"40","author":"Y Touchefeu","year":"2014","unstructured":"Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis\u2014current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409\u201321. https:\/\/doi.org\/10.1111\/apt.12878.","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"1133_CR26","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.1158\/1078-0432.ccr-15-0724","volume":"21","author":"SK Pal","year":"2015","unstructured":"Pal SK, Li SM, Wu X, Qin H, Kortylewski M, Hsu J, et al. Stool bacteriomic profiling in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors. Clin Cancer Res. 2015;21(23):5286\u201393. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-0724.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1133_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.bbmt.2015.04.016","volume":"21","author":"RR Jenq","year":"2015","unstructured":"Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(8):1373\u201383. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.016.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1133_CR28","first-page":"59","volume":"14","author":"KR Secombe","year":"2018","unstructured":"Secombe KR, Coller JK, Gibson RJ, Stringer AM, Al-Dasooqi N, Mayo BJ, Wardill HR. Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. Asia Pac J Clin Oncol. 2018;14:59.","journal-title":"Asia Pac J Clin Oncol."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-020-01133-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T23:40:42Z","timestamp":1626565242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-020-01133-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,18]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01133-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,18]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kate Secombe, Imogen Ball, Joseph Shirren and Anthony Wignall declare that they have no conflicts of interest. Joanne Bowen has received research funding from Puma Biotechnology, AstraZeneca, Helsinn and Pfizer. Dorothy Keefe is a consultant for and owns stock in Entrinsic Health Solutions, has received consulting fees from Zealand Pharma and is on the speakers\u2019 bureau of Mundipharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}